Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

811.50 -7.85 (-0.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 625,803
Open 816.01
Bid (Size) 798.75 (1)
Ask (Size) 812.50 (5)
Prev. Close 819.35
Today's Range 804.64 - 825.08
52wk Range 538.01 - 835.00
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?
Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease. 
Via The Motley Fool
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire

Performance

YTD
+12.63%
+12.63%
1 Month
+6.72%
+6.72%
3 Month
+12.51%
+12.51%
6 Month
+17.30%
+17.30%
1 Year
+17.20%
+17.20%

More News

Read More
Regeneron Pharmaceuticals Unusual Options Activity For March 28
Via Benzinga
Regeneron Pharmaceuticals, Hess And 1 Of World's Biggest Bank: CNBC's 'Final Trades'
Via Benzinga
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
From Sonoma Biotherapeutics, Inc.
Via Business Wire
Analyst Ratings for Regeneron Pharmaceuticals
Via Benzinga
Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Via MarketBeat
UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug
Via Benzinga
Baird Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Regeneron Pharmaceuticals (NASDAQ: REGN) is a Leading Gainer in 3/23 Morning Trading
Via Investor Brand Network
Why Shares of Regeneron Are Rising Thursday
Via The Motley Fool
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 27, 2023
Via Benzinga
Pinterest To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
Could This Label Expansion Be a Growth Catalyst for Sanofi Stock?
Via The Motley Fool
Wall Street Has High Hopes for These 2 Nasdaq Stocks
Via The Motley Fool
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Via Benzinga
Stock Market Split As Fed Hikes Rates, Banks Keep Tumbling; Nvidia, On Holding In Focus: Weekly Review
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023
Via Benzinga
Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In
Via Benzinga
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
Via Benzinga
US Stocks On Track For Weak Start Friday Amid Renewed Banking Concerns And Contagion Fears
Via Benzinga
Why Are Stocks Up Today?
Via InvestorPlace
REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.